{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:14:06Z","timestamp":1793060046120,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The optimal ribavirin dosing regimen for the treatment of chronic hepatitis E virus (HEV) infection in solid organ transplant (SOT) is unknown. We modelled ribavirin plasma concentrations versus virologic response and haemoglobin concentrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Data were collected in a retrospective, multicentre study of adult SOT recipients with chronic HEV infection treated with ribavirin between September 2009 and November 2019. Population pharmacokinetic and pharmacodynamic analyses were conducted using nonlinear mixed-effects modelling. Simulations were performed to select the most suitable RBV dosing regimen considering efficacy and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 107 chronically HEV-infected SOT recipients with 305 ribavirin plasma levels, 592 viral load and 443 haemoglobin concentrations were included. Sustained virologic response was achieved in 68.2% of the subjects. Owing to a low IC50, the decline in viral load was independent of ribavirin concentration and dose, whereas haemoglobin decreased with increasing ribavirin concentration and dose. A model-supported ribavirin dose for 180\u2005days of 600\u2005mg\/day and kidney function (eGFR)\u200a\u2265\u200a60\u2005mL\/min\/1.73 m2, 400\u2005mg\/day and eGFR 30\u201359\u2005mL\/min\/1.73 m2 and 200\u2005mg\/day and eGFR \u226430\u2005mL\/min\/1.73 m2 showed good efficacy and low toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study constitutes a valuable first step in determining the optimal ribavirin treatment regimen for chronic HEV infections in SOT recipients. Our model suggests a lower dose of ribavirin and longer treatment duration compared to the suggested dosing regimen in the EASL Clinical Practice Guidelines on HEV infection. Implementing our dosing regimen in clinical practice will allow for lower toxicity rates, improved tolerability and equal efficacy in chronically HEV-infected SOT recipients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trial number<\/jats:title>\n                  <jats:p>MEC-2018-1326<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf183","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T01:16:00Z","timestamp":1751159760000},"page":"2158-2168","source":"Crossref","is-referenced-by-count":6,"title":["Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0925-3771","authenticated-orcid":false,"given":"Midas B","family":"Mulder","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]},{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]},{"name":"Erasmus MC Rotterdam Clinical Pharmacometrics Group , University Medical Center Rotterdam, Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"van Noort","sequence":"additional","affiliation":[{"name":"LAP&P Consultants BV , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1932-7412","authenticated-orcid":false,"given":"Robert A","family":"de Man","sequence":"additional","affiliation":[{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]},{"name":"Department of Hepatology, Erasmus MC, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Organs Transplantation, CHU Rangueil, INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Universit\u00e9 Paul Sabatier , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"de Bruijne","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-5234","authenticated-orcid":false,"given":"Marjolein","family":"Knoester","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4240-7506","authenticated-orcid":false,"given":"Hans","family":"Blokzijl","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vanwolleghem","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital of Antwerp , Edegem ,","place":["Belgium"]},{"name":"Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp , Antwerp ,","place":["Belgium"]},{"name":"European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Department of Gastroenterology and Hepatology, University Hospital of Antwerp, Edegem ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Roosens","sequence":"additional","affiliation":[{"name":"Laboratory for TDM and Toxicology, Antwerp University Hospital , Edegem ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Izopet","sequence":"additional","affiliation":[{"name":"Department of Virology, CHU Purpan, INSERM U1043, IFR\u2013BMT, University Paul Sabatier , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Gandia","sequence":"additional","affiliation":[{"name":"Department of Toxicology, CHU Purpan, INSERM U1043, IFR\u2013BMT, University Paul Sabatier , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-5536","authenticated-orcid":false,"given":"Annemiek A","family":"van der Eijk","sequence":"additional","affiliation":[{"name":"Department of Virology, Erasmus MC, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herold J","family":"Metselaar","sequence":"additional","affiliation":[{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]},{"name":"Department of Hepatology, Erasmus MC, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-2571","authenticated-orcid":false,"given":"Maurice J","family":"Ahsman","sequence":"additional","affiliation":[{"name":"LAP&P Consultants BV , Leiden ,","place":["The Netherlands"]},{"name":"Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1387-1369","authenticated-orcid":false,"given":"Tamara J","family":"van Steeg","sequence":"additional","affiliation":[{"name":"LAP&P Consultants BV , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1871-1962","authenticated-orcid":false,"given":"Dennis A","family":"Hesselink","sequence":"additional","affiliation":[{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]},{"name":"Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-8443","authenticated-orcid":false,"given":"Brenda C M","family":"de Winter","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]},{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]},{"name":"Erasmus MC Rotterdam Clinical Pharmacometrics Group , University Medical Center Rotterdam, Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"2025080100172775200_dkaf183-B1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S1473-3099(08)70255-X","article-title":"Hepatitis E: an emerging infection in developed countries","volume":"8","author":"Dalton","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2025080100172775200_dkaf183-B2","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1111\/trf.12733","article-title":"Past and present of hepatitis E in The Netherlands","volume":"54","author":"Hogema","year":"2014","journal-title":"Transfusion"},{"key":"2025080100172775200_dkaf183-B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jcv.2016.06.010","article-title":"Hepatitis E virus: assessment of the epidemiological situation in humans in Europe, 2014\/15","volume":"82","author":"Adlhoch","year":"2016","journal-title":"J Clin Virol"},{"key":"2025080100172775200_dkaf183-B4","doi-asserted-by":"publisher","first-page":"30561","DOI":"10.2807\/1560-7917.ES.2017.22.26.30561","article-title":"Hepatitis E virus infection in Europe: surveillance and descriptive epidemiology of confirmed cases, 2005 to 2015","volume":"22","author":"Aspinall","year":"2017","journal-title":"Euro Surveill"},{"key":"2025080100172775200_dkaf183-B5","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","article-title":"EASL clinical practice guidelines on hepatitis E virus infection","volume":"68","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"2025080100172775200_dkaf183-B6","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1053\/j.gastro.2011.02.050","article-title":"Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants","volume":"140","author":"Kamar","year":"2011","journal-title":"Gastroenterology"},{"key":"2025080100172775200_dkaf183-B7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-153-2-201007200-00257","article-title":"Brief communication: case reports of ribavirin treatment for chronic hepatitis E","volume":"153","author":"Mallet","year":"2010","journal-title":"Ann Intern Med"},{"key":"2025080100172775200_dkaf183-B8","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1053\/j.gastro.2010.08.002","article-title":"Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection","volume":"139","author":"Kamar","year":"2010","journal-title":"Gastroenterology"},{"key":"2025080100172775200_dkaf183-B9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/liv.12114","article-title":"Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience","volume":"33","author":"Pischke","year":"2013","journal-title":"Liver Int"},{"key":"2025080100172775200_dkaf183-B10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","article-title":"Ribavirin for chronic hepatitis E virus infection in transplant recipients","volume":"370","author":"Kamar","year":"2014","journal-title":"N Engl J Med"},{"key":"2025080100172775200_dkaf183-B11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1128\/AAC.01795-13","article-title":"Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon","volume":"58","author":"Debing","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025080100172775200_dkaf183-B12","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/cid\/ciz953","article-title":"Ribavirin for hepatitis E virus infection after organ transplantation: a large European retrospective multicenter study","volume":"71","author":"Kamar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025080100172775200_dkaf183-B13","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"2025080100172775200_dkaf183-B14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"2025080100172775200_dkaf183-B15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00535-003-1363-9","article-title":"Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C","volume":"39","author":"Takaki","year":"2004","journal-title":"J Gastroenterol"},{"key":"2025080100172775200_dkaf183-B16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jvh.13432","article-title":"Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection","volume":"28","author":"Mulder","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025080100172775200_dkaf183-B17","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2019"},{"key":"2025080100172775200_dkaf183-B18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","article-title":"Likelihood based approaches to handling data below the quantification limit using NONMEM VI","volume":"35","author":"Ahn","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2025080100172775200_dkaf183-B19","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1128\/AAC.04618-14","article-title":"Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection","volume":"59","author":"Wu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025080100172775200_dkaf183-B20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jtbi.2007.03.006","article-title":"Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy","volume":"247","author":"Dahari","year":"2007","journal-title":"J Theor Biol"},{"key":"2025080100172775200_dkaf183-B21","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.healun.2015.01.009","article-title":"Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency","volume":"34","author":"Burrows","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"2025080100172775200_dkaf183-B22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1053\/j.ajkd.2003.09.019","article-title":"Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function","volume":"43","author":"Kamar","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2025080100172775200_dkaf183-B23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/00003088-200544040-00006","article-title":"Pharmacokinetic\/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C","volume":"44","author":"Tod","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2025080100172775200_dkaf183-B24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/psp4.12058","article-title":"Modeling ribavirin-induced anemia in patients with chronic hepatitis C virus","volume":"5","author":"Wu","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025080100172775200_dkaf183-B25","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1053\/j.gastro.2014.02.036","article-title":"Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus","volume":"146","author":"Wang","year":"2014","journal-title":"Gastroenterology"},{"key":"2025080100172775200_dkaf183-B26","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1053\/jhep.2002.32672","article-title":"Mechanism of action of ribavirin in the combination treatment of chronic HCV infection","volume":"35","author":"Lau","year":"2002","journal-title":"Hepatology"},{"key":"2025080100172775200_dkaf183-B27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1086\/382595","article-title":"Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha","volume":"189","author":"Tanabe","year":"2004","journal-title":"J Infect Dis"},{"key":"2025080100172775200_dkaf183-B28","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/apt.14288","article-title":"Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals","volume":"46","author":"van Tilborg","year":"2017","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/8\/2158\/63568936\/dkaf183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/8\/2158\/63568936\/dkaf183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T04:17:38Z","timestamp":1754021858000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/8\/2158\/8172619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf183","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,6,24]]}}}